ArticleCase reports in hematology2026
Extranodal Male Genital Involvement With Diffuse Large B-Cell Lymphoma.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Painful penile mass as an initial manifestation of systemic diffuse large B-cell lymphoma: a case report.Frontiers in medicine · 2026Article
- Extranodal Male Genital Involvement With Diffuse Large B-Cell Lymphoma.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary penile diffuse large B-cell lymphoma (DLBCL) is an exceptionally rare extranodal presentation that can be challenging to diagnose due to its nonspecific symptoms. We report the case of an 84-year-old male who initially presented with phimosis who subsequently developed a nonhealing surgical wound and B symptoms. Imaging and biopsy ultimately revealed Stage IVB activated B-cell type DLBCL. He was treated with dose-reduced rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (modified R-mini-CHOP). Despite his advanced disease, he achieved a partial metabolic response with negative minimal residual disease. We also summarize prior reported cases of penile DLBCL, highlighting patterns in disease presentation and treatment approaches. This case emphasizes the importance of maintaining a broad differential for penile lesions to avoid delays in diagnosis and treatment, and it illustrates the integration of novel agents such as polatuzumab vedotin for frail or elderly patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.